Drugs / AC0058TA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03878303 | Nov 2018 → Dec 2020 | systemic lupus erythematosus | ACEA Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT02847325 | May 2016 → Apr 2017 | — | ACEA Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AC0058TA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02847325 ↗ |
| Action | Inhibit | “potently, selectively and irreversibly inhibits Bruton's tyrosine kinase (BTK) phosphorylation” NCT02847325 ↗ |
| Modality | Small molecule | “AC0058TA is a small molecule compound” NCT02847325 ↗ |
| Route | Oral | “AC0058TA administered orally” NCT02847325 ↗ |
| Target | BTK | “inhibits Bruton's tyrosine kinase (BTK) phosphorylation” NCT02847325 ↗ |